Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
December 2015 Volume 14 Number 12 | Advertisement | ||||||||||||||||||||||||||||||||||||
In this issue Comment News and Analysis Research Highlights Perspectives Reviews
|
| ||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
Comment: Industry-academia collaborations for biomarkers Khusru Asadullah, Andreas Busch, Matthias Gottwald, Petra Reinke & Lilla Landeck p805 | doi:10.1038/nrd4727 Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success. Abstract | Full Text | PDF | Supplementary information | |||||||||||||||||||||||||||||||||||||
NEWS AND ANALYSIS | Top | ||||||||||||||||||||||||||||||||||||
The phenotypic screening pendulum swings Asher Mullard p807 | doi:10.1038/nrd4783 Industry and academic scientists are working together to figure out when and how best to use phenotypic screening in drug discovery. | |||||||||||||||||||||||||||||||||||||
Pioneering biased ligand offers efficacy with reduced on-target toxicity Katie Kingwell p809 | doi:10.1038/nrd4784 Clinical success with Trevena's 'biased' G protein-coupled receptor ligand highlights the potential of exploring the nuances of receptor pharmacology. | |||||||||||||||||||||||||||||||||||||
NEWS IN BRIEF Regulators approve the first cancer-killing virus Asher Mullard p811 | doi:10.1038/nrd4805 | |||||||||||||||||||||||||||||||||||||
Priority review voucher pitfalls Asher Mullard p811 | doi:10.1038/nrd4806 | |||||||||||||||||||||||||||||||||||||
FDA approves anticoagulant antidote Asher Mullard p811 | doi:10.1038/nrd4807 | |||||||||||||||||||||||||||||||||||||
BIOBUSINESS BRIEFS Market watch: Where is personalized medicine in industry heading? Christopher-Paul Milne, Joshua P. Cohen & Ranjana Chakravarthy p812 | doi:10.1038/nrd4759 | |||||||||||||||||||||||||||||||||||||
BIOBUSINESS BRIEFS Patent watch: Australia's highest court decides isolated nucleic acids are not patent eligible Leigh Guerin & Mark Wickham p813 | doi:10.1038/nrd4790 | |||||||||||||||||||||||||||||||||||||
AN AUDIENCE WITH Karen Midthun p814 | doi:10.1038/nrd4792 Karen Midthun, outgoing Director of the FDA's Center for Biologics Evaluation and Research, reflects on 22 years at the agency. | |||||||||||||||||||||||||||||||||||||
FROM THE ANALYST'S COUCH Two decades of new drug development for central nervous system disorders Aaron S. Kesselheim, Thomas J. Hwang & Jessica M. Franklin p815 | doi:10.1038/nrd4793 This article analyses the characteristics of the pipeline for experimental drugs for central nervous system disorders and how they have fared in the clinical phases prior to FDA approval over the past two decades. | |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
PERSPECTIVES | Top | ||||||||||||||||||||||||||||||||||||
OPINION Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? David Brown p821 | doi:10.1038/nrd4675 Drug resistance is threatening to sideline the currently available antibiotics, and new antibiotics are unlikely to become available before the current arsenal becomes ineffective. Brown proposes the use of approved drugs or neutraceuticals as antibiotic resistance breakers — compounds that could be administered alongside current antibiotics to prolong their useful lifespan — to bridge the gap. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
OPINION Pioneering government-sponsored drug repositioning collaborations: progress and learning Donald E. Frail, Madeleine Brady, K. Jane Escott, Alison Holt, Hitesh J. Sanganee, Menelas N. Pangalos, Chris Watkins & Craig D. Wegner p833 | doi:10.1038/nrd4707 A new model for translational research and drug repositioning has recently been established based on three-way partnerships between public funders, the pharmaceutical industry and academic investigators. This article discusses the progress with two pioneering initiatives — one involving the UK Medical Research Council and one involving the US National Center for Advancing Translational Sciences — and the unique requirements and challenges for this model. Abstract | Full Text | PDF | Supplementary information | |||||||||||||||||||||||||||||||||||||
REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
Clinical experiences with systemically administered siRNA-based therapeutics in cancer Jonathan E. Zuckerman & Mark E. Davis p843 | doi:10.1038/nrd4685 Several Phase I trials evaluating systemically administered siRNA-based therapeutics for cancer have recently been completed. Here, Zuckerman and Davis critically assess these studies and discuss key lessons learnt and implications for the future development of siRNA-based therapeutics and clinical trial design. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Complement, a target for therapy in inflammatory and degenerative diseases B. Paul Morgan & Claire L. Harris p857 | doi:10.1038/nrd4657 The complement cascade, a key regulator of innate immunity, is a rich source of potential therapeutic targets for diseases including autoimmune, inflammatory and degenerative disorders. Morgan and Harris discuss the progress made in modulating the complement system and the existing challenges, including dosing, localization of the drug to the target and how to interfere with protein–protein interactions. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Corrigendum: Cancer drug developers counteract kinase gatekeeper mutations Asher Mullard p877 | doi:10.1038/nrd4797 Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Corrigendum: Do you want chips with that? Asher Mullard p877 | doi:10.1038/nrd4808 Full Text | PDF | |||||||||||||||||||||||||||||||||||||
Advertisement | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
|
*2013 Journal Citation Report (Thomson Reuters, 2014) |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
No comments:
Post a Comment
Keep a civil tongue.